Posted by Michael Wonder on 05 Jul 2024
CSL Behring announces first two patients treated with Hemgenix (etranacogene dezaparvovec) gene therapy for haemophilia B in Europe
4 July 2024 - CSL Behring today announced that two haemophilia B patients were treated with the gene therapy Hemgenix (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France.
This milestone achievement makes Hemgenix the first gene therapy administered as a treatment in a real world setting for haemophilia B in Europe.
